AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22088414 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosimilar etanercept (25 mg)
Number of subjects: 23
Study 19299497 — intervention group
Group type: EXPERIMENTAL
Intervention: Heliox (79% He and 21% O2)
Number of subjects: 12
Study 19299497 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 12
Study 17300242 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (20% ALA solution under occlusive dressing for 3 h followed by helium-neon laser irradiation at 100 J cm(‐2) and 100 mW power)
Number of subjects: 86
Study 17300242 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (after two treatments)
Number of subjects: 86
Study 17300242 — intervention group
Group type: COMPARATOR
Intervention: Control (CO2 laser treatment)
Number of subjects: 86
Study 17300242 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT
Number of subjects: 86
Study 14722514 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/d)
Number of subjects: 24
Study 14722514 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 11510914 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbent dialysis
Number of subjects: 20
Study 11510914 — intervention group
Group type: COMPARATOR
Intervention: Standardized medical treatment
Number of subjects: 20
Study 9776434 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of ketorolac
Number of subjects: 57
Study 9776434 — intervention group
Group type: COMPARATOR
Intervention: 75 mg of diclofenac
Number of subjects: 57
Study 7821197 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors (HD)
Number of subjects: 170
Study 7821197 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-dependent diabetes mellitus (IDDM)
Number of subjects: 170
Study 7821197 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-insulin-dependent diabetes mellitus (NIDDM)
Number of subjects: 170
Study 7821197 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of blood glucose in poorly controlled IDDM patients
Number of subjects: 170
Study 7821197 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalization of blood glucose in poorly controlled NIDDM patients
Number of subjects: 170
Study 7821197 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorly controlled NIDDM patients
Number of subjects: 170
Study 2900816 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg of broxaterol hydrochloride
Number of subjects: 12
Study 2900816 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg of broxaterol hydrochloride
Number of subjects: 12
Study 2900816 — intervention group
Group type: COMPARATOR
Intervention: 200 mcg of salbutamol
Number of subjects: 12
Study 29247365 — intervention group
Group type: EXPERIMENTAL
Intervention: On-lay autologous full-thickness skin graft
Number of subjects: 53
Study 29247365 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh
Number of subjects: 53
Study 28431145 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention aimed to reduce body weight
Number of subjects: 407
Study 28431145 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucosamine sulphate
Number of subjects: 407
Study 28431145 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 407
Study 26408621 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia
Number of subjects: 90
Study 26408621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway under general anesthesia
Number of subjects: 90
Study 26408621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway under general anesthesia combined with epidural block
Number of subjects: 90
Study 24461666 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor 150 mg twice daily
Number of subjects: 21
Study 24461666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 20684151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere (TGM) 0.04% pump
Number of subjects: 170
Study 20684151 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1% plus benzoyl peroxide 2.5% gel (ADA-BPO 0.1%/2.5%)
Number of subjects: 170
Study 18064474 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg x 2 daily during radiation
Number of subjects: 35
Study 18064474 — intervention group
Group type: EXPERIMENTAL
Intervention: Uracil-tegafur 300 mg/m2 daily during radiation
Number of subjects: 35
Study 17178006 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph design modifications (changing a pie chart to a bar graph)
Number of subjects: 543
Study 17178006 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph design modifications (changing the y axis to represent an increase)
Number of subjects: 543
Study 17178006 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph design modifications (adding a footnote to explain an acronym)
Number of subjects: 543
Study 17178006 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph design modifications (matching the y axis range of two adjacent graphs)
Number of subjects: 543
Study 17178006 — intervention group
Group type: COMPARATOR
Intervention: Control group (booklet of 12 graphs from original publications)
Number of subjects: 543
Study 12591047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 12591047 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 30
Study 12591047 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 30
Study 10966543 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 120
Study 10966543 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 120
Study 10966543 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 120
Study 8780092 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 188
Study 8780092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 1611979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin (POR 8) at a standard concentration of 0.2 i.u./ml
Number of subjects: 231
Study 1611979 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (Control)
Number of subjects: 231
Study 6487471 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 27
Study 6487471 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 27
Study 6487471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30456964 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME) by certified diabetes educators (CDE) plus usual care
Number of subjects: 140
Study 30456964 — intervention group
Group type: COMPARATOR
Intervention: Usual care from family physicians
Number of subjects: 140
Study 30456964 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes self-management education (DSME)
Number of subjects: 140
Study 26975694 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (six sessions)
Number of subjects: 0
Study 26975694 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment (without psychoeducation)
Number of subjects: 0
Study 24964164 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) training
Number of subjects: 199
Study 24964164 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 199
Study 22846637 — intervention group
Group type: EXPERIMENTAL
Intervention: Acoustic coordinated reset (CR) neuromodulation
Number of subjects: 0
Study 22846637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19713225 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein in the highest quintile
Number of subjects: 515
Study 19713225 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of myocardial infarction before age 60
Number of subjects: 515
Study 19713225 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure in the highest quintile
Number of subjects: 515
Study 19713225 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 515
Study 19713225 — intervention group
Group type: COMPARATOR
Intervention: Total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, glucose, smoking
Number of subjects: 515
Study 18922613 — intervention group
Group type: COMPARATOR
Intervention: Tooth Mousse (TM) applied for 60 min daily for 7 days; smear layer retained (group 1)
Number of subjects: 0
Study 18922613 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth Mousse (TM) applied for 60 min daily for 7 days; smear layer removed (group 2)
Number of subjects: 0
Study 18922613 — intervention group
Group type: COMPARATOR
Intervention: Preconditioning with 30-40% phosphoric acid (PA)
Number of subjects: 0
Study 18922613 — intervention group
Group type: COMPARATOR
Intervention: Preconditioning with 20% polyacrylic acid (CC)
Number of subjects: 0
Study 15795715 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator (tPA)
Number of subjects: 0
Study 15795715 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 12920494 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via Volumatic
Number of subjects: 44
Study 12920494 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via pMDI
Number of subjects: 44
Study 12920494 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via pMDI plus Volumatic
Number of subjects: 44
Study 12920494 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Turbuhaler
Number of subjects: 44
Study 12920494 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol via Diskus
Number of subjects: 44
Study 12920494 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol via all devices
Number of subjects: 44
Study 10392812 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) treatment
Number of subjects: 608
Study 10392812 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (XRT) to the chest wall and/or axillary lymph nodes
Number of subjects: 608
Study 10392812 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative irradiation (XRT) to the internal mammary nodes
Number of subjects: 608
Study 10392812 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal status and pT
Number of subjects: 608
Study 10392812 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular tumour extension (ECE) in node-positive patients
Number of subjects: 608
Study 8669405 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (5% of total daily energy intake)
Number of subjects: 48
Study 8669405 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (5% of total daily energy intake)
Number of subjects: 48
Study 1854979 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammography screening
Number of subjects: 40318
Study 1854979 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 40318
Study 1854979 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammography screening (for women older than 50)
Number of subjects: 40318
Study 1854979 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-view mammography screening (for women under 50)
Number of subjects: 40318
Study 6824898 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade (T3-4 to L1-2) continuing for 48 hours postoperatively
Number of subjects: 45
Study 6824898 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 45
Study 6824898 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural blockade with vagus nerve block
Number of subjects: 45
Study 30180110 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Responsible Marijuana Vendor (RMV) training
Number of subjects: 225
Study 27993631 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature of 33°C
Number of subjects: 939
Study 27993631 — intervention group
Group type: COMPARATOR
Intervention: Target temperature of 36°C
Number of subjects: 939
Study 27993631 — intervention group
Group type: EXPERIMENTAL
Intervention: Infections (pneumonia, severe sepsis, septic shock)
Number of subjects: 939
Study 27993631 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT) and C-reactive protein (CRP) levels
Number of subjects: 939
Study 26430749 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-Hz rTMS to the left temporoparietal cortex region
Number of subjects: 7
Study 26430749 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation to the left temporoparietal cortex region
Number of subjects: 7
Study 23849700 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow spindles in epileptics
Number of subjects: 24
Study 23849700 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spindles
Number of subjects: 24
Study 23849700 — intervention group
Group type: COMPARATOR
Intervention: Slow spindles in healthy volunteers
Number of subjects: 24
Study 22039668 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombined interferon alpha‐2b and ribavirin
Number of subjects: 50
Study 22039668 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha‐2b and ribavirin
Number of subjects: 50
Study 22039668 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 50
Study 18651884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tao Brush
Number of subjects: 200
Study 18651884 — intervention group
Group type: COMPARATOR
Intervention: Pipelle
Number of subjects: 200
Study 18651884 — intervention group
Group type: EXPERIMENTAL
Intervention: Both samplers
Number of subjects: 200
Study 17187330 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation for 3 weeks (n=127)
Number of subjects: 261
Study 17187330 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation for 4 weeks (n=134)
Number of subjects: 261
Study 17187330 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient rehabilitation (3 weeks and 4 weeks combined)
Number of subjects: 261
Study 17187330 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 261
Study 12830446 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal hemodialysis with monitoring
Number of subjects: 14
Study 11728147 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol + trimetazidine
Number of subjects: 426
Study 11728147 — intervention group
Group type: COMPARATOR
Intervention: metoprolol + placebo
Number of subjects: 426
Study 9151364 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg THIP
Number of subjects: 0
Study 9151364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7963155 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.5 mg/kg/day)
Number of subjects: 24
Study 7963155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2953691 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-resistance (HR) training
Number of subjects: 21
Study 2953691 — intervention group
Group type: EXPERIMENTAL
Intervention: Explosive strength (EX) training
Number of subjects: 21
Study 2953691 — intervention group
Group type: COMPARATOR
Intervention: Both groups together
Number of subjects: 21
Study 31748705 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide
Number of subjects: 126
Study 29275402 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-holding (group I)
Number of subjects: 86
Study 29275402 — intervention group
Group type: COMPARATOR
Intervention: Non-hand-holding (group II)
Number of subjects: 86
Study 27863024 — intervention group
Group type: EXPERIMENTAL
Intervention: PCP visits + specialist tele-visits
Number of subjects: 40
Study 27863024 — intervention group
Group type: COMPARATOR
Intervention: PCP visits only
Number of subjects: 40
Study 24996454 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus guideline target volume delineation atlas
Number of subjects: 13
Study 24996454 — intervention group
Group type: COMPARATOR
Intervention: Control group (not following the atlas)
Number of subjects: 13
Study 23471817 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe with clip
Number of subjects: 149
Study 23471817 — intervention group
Group type: COMPARATOR
Intervention: Syringe without clip
Number of subjects: 149
Study 23471817 — intervention group
Group type: COMPARATOR
Intervention: Dosing cup
Number of subjects: 149
Study 21679320 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpine skiing training (12 weeks, 2-3 times a week, ∼3.5 hours per session)
Number of subjects: 22
Study 21679320 — intervention group
Group type: COMPARATOR
Intervention: Control group (inactive, n=20, 67 ± 4 years)
Number of subjects: 22
Study 18504547 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml white wine (approximately 25 g alcohol/day)
Number of subjects: 36
Study 17323844 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program (24 sessions of 30 minutes each over 16 weeks)
Number of subjects: 66
Study 17323844 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 12699806 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 130
Study 12699806 — intervention group
Group type: COMPARATOR
Intervention: Vacuum delivery
Number of subjects: 130
Study 12699806 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps delivery (after exclusion of 'failed vacuum')
Number of subjects: 130
Study 11063191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine in a smoke-free environment
Number of subjects: 17
Study 11063191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine in a smoking environment
Number of subjects: 17
Study 11063191 — intervention group
Group type: COMPARATOR
Intervention: Baseline BP in a smoke-free environment
Number of subjects: 17
Study 11063191 — intervention group
Group type: COMPARATOR
Intervention: Baseline BP in a smoking environment
Number of subjects: 17
Study 8883001 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity (HI) exercise
Number of subjects: 8
Study 8883001 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity (LI) exercise
Number of subjects: 8
Study 1373337 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of high-osmolarity ionic contrast medium
Number of subjects: 60
Study 1373337 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of low-osmolarity non-ionic contrast medium
Number of subjects: 60
Study 1373337 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower fixed dose of low-osmolarity non-ionic contrast medium
Number of subjects: 60
Study 1373337 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional radiograph during abdominal compression
Number of subjects: 60
Study 3533471 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide (0.3 microgram/kg body weight)
Number of subjects: 48
Study 3533471 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (5.0 micrograms/kg body weight)
Number of subjects: 48
Study 30217232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 29231517 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-directional stimulation technique
Number of subjects: 60
Study 29231517 — intervention group
Group type: COMPARATOR
Intervention: Routine needling technique
Number of subjects: 60
Study 24297951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcium/magnesium before and after oxaliplatin
Number of subjects: 353
Study 24297951 — intervention group
Group type: COMPARATOR
Intervention: Placebo before and after oxaliplatin
Number of subjects: 353
Study 24297951 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/magnesium before and placebo after
Number of subjects: 353
Study 24297951 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium/magnesium
Number of subjects: 353
Study 22323092 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) administered intravenously, titrated according to a weight-adjusted dosing nomogram to a target aPTT of 1.5-2 times the upper limit of normal (approximately 50-70 s), median treatment duration of 42 hours.
Number of subjects: 4985
Study 22323092 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) treatment with aPTT categorized as persistently below <50 s for recurrent ischemic events.
Number of subjects: 4985
Study 22323092 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) treatment with aPTT categorized as persistently above >70 s for major hemorrhagic events.
Number of subjects: 4985
Study 20196118 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Number of subjects: 863
Study 20196118 — intervention group
Group type: COMPARATOR
Intervention: 16 weeks of peginterferon alfa‐2a (40KD) 180 microg/week plus ribavirin 800 mg/day
Number of subjects: 863
Study 20196118 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of treatment in genotype 2
Number of subjects: 863
Study 20196118 — intervention group
Group type: COMPARATOR
Intervention: 16 weeks of treatment in genotype 2
Number of subjects: 863
Study 20196118 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of treatment in genotype 3
Number of subjects: 863
Study 20196118 — intervention group
Group type: COMPARATOR
Intervention: 16 weeks of treatment in genotype 3
Number of subjects: 863
Study 18613251 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical patient-level data extrapolation methodology
Number of subjects: 23000
Study 18613251 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel combination of models estimating hazard rate
Number of subjects: 23000
Study 16818836 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Number of subjects: 44
Study 16818836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 14520130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 16
Study 14520130 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 16
Study 14520130 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone and Fluoxetine
Number of subjects: 16
Study 10919932 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid‐enriched oil (supplement)
Number of subjects: 36